NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_ER_80hr,"Data from the assay component ACEA_ER_80hr was analyzed into 2 assay endpoints. 
This assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,,,Active,43.23411416786667,1.695987966503861,2.7859434245044863,0.44497229275018707,8.497331156775092,46.93247259703333,percent_activity,2,25.491993470325276,"[""Less than 50% efficacy""]",0.5435155891213599,0.5435155891213599,-0.15245614722405937,20,nuclear receptor
ATG_RARg_TRANS_up,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000957.1, , , ,,,Active,1.7425143716929474,1.5074648992551916,0.9529926941162605,-0.0209104287605777,0.23118473571807732,1.4520953098177776,log2_fold_induction,0.301029995663981,1.1559236785903866,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",0.016001831895301383,-0.04342393191667532,-0.1404758278953154,20,nuclear receptor
CCTE_Shafer_MEA_acute_LDH_up,"Data from the assay component CCTE_Shafer_MEA_acute_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_LDH_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to understand cell viability.",, , , ,,,Active,7.9473597578352395,1.4977031786717636,14.459474356043067,1.1601525053776482,1.7687883400419717,7.9032944322878675,percent_activity,1.60205999132796,5.306365020125915,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",1.1991631571986543,1.1991631571986543,1.0373076609661571,20,cell cycle
LTEA_HepaRG_ADK_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006712.2, , , ,,,Active,1.06250319599009,2.1333139173335027,12.665950217182514,1.10263777672419,0.166017635341442,0.68817510450991,log2_fold_induction,1.47712125471966,0.498052906024326,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.09584398910423,1.09584398910423,0.983357289816184,20,kinase
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,1.61476285577,1.793024063736678,32.69524259692158,1.51448456415217,0.300193564683644,1.61454526430768,log2_fold_induction,2,0.900580694050932,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.52707378983762,1.52707378983762,1.39520404753319,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2, , , ,"[131,131]",,Active,1.17602729170723,1.2385847201125966,33.30636224983014,1.52252720125621,0.316497604782422,1.17583963125641,log2_fold_induction,2,0.949492814347266,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60032187315328,1.60032187315328,1.40324688728791,20,cyp
NVS_ENZ_hMAPKAPK2_Activator,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",NP_116584.2, , , ,,,Active,23.2284923752822,1.16142461876411,1.0609096041326664,0.0256783809806535,1.82329603738036,26.3157894736842,percent_activity,0.301029995663981,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",0.124682159861221,-0.0382504173804784,-0.0936019327673415,20,kinase
NVS_ENZ_hMMP2,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_004521.1, , , ,,,Active,114.236418744306,5.7118209372152995,10.803064949393807,1.03354698713219,1.51774784482759,95.197015621357,percent_activity,1.69897000433602,20,,0.214199946046168,-0.648283514146451,-0.127874299950419,20,protease
NVS_ENZ_hPTEN,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",NP_000305.3, , , ,,,Active,107.906244648424,3.1826141579845877,1.6355718742935297,0.213669633709063,5.65081823159468,89.921875,percent_activity,0.301029995663981,33.9049093895681,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",0.171297512444428,0.122471107145716,0.0943893192906828,20,phosphatase
NVS_ENZ_hPTPN11_Activator,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",NP_002825.3, , , ,,,Active,24.2031029481194,1.21015514740597,15.48739449724346,1.18997836090657,2.73358049167327,20.1692524682652,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",2.01894445560057,0.834718228367045,0.0223304944995371,20,phosphatase
NVS_NR_hPXR,"Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,55.0555292928642,1.4500116918203108,8.924702106124586,0.950593728893428,6.32817073170732,51.131221719457,percent_activity,1.30102999566398,37.9690243902439,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.994297207210711,0.915462322947791,0.830332544570629,20,nuclear receptor
Tanguay_ZF_120hpf_ActivityScore,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,28.2286705680575,1.411433528402875,0.005512055663033785,-2.25868640539173,2.2401450326604,98.0567707041548,percent_activity,-1.22184874961636,20,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""AC50 less than lowest concentration tested"",""Noisy data"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Noisy data"",""AC50 less than lowest concentration tested""]",-2.19578953873242,-2.34107151186968,-2.41429650160578,20,malformation
Tanguay_ZF_120hpf_MORT_up,"Data from the assay component Tanguay_ZF_120hpf_MORT_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_MORT_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,65.2725991744151,1.2380652733919444,0.006035949097327607,-2.21925443139528,10.5442904469143,52.8483973266515,percent_activity,-1.22184874961636,52.7214522345715,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",-2.140844936475,-2.22261494298525,-2.33929485971185,20,malformation
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,37.8925521493048,1.511061603785565,0.8428157887302493,-0.0742673372141553,4.17946253309319,31.5771268179,percent_activity,0,25.0767751985591,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model""]",-0.037826493892274,-0.112493288916853,-0.193547650926317,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,77.7381173152322,3.201893354431503,25.387483041011905,1.40461964630169,4.04646609105207,64.781764434,percent_activity,1.47712125471966,24.2787965463124,"[""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.36177011120532,1.31303237143682,1.28533933260073,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,83.8229367297812,3.4772280979082226,25.504468414204823,1.40661627602704,4.0177086637968,69.852447312,percent_activity,1.47712125471966,24.1062519827808,"[""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.35737052635757,1.30976101293559,1.28733596234283,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,78.6373950812423,3.205089379835691,25.477915120418665,1.40616388642848,4.08919407864135,65.5311625719,percent_activity,1.47712125471966,24.5351644718481,"[""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.36323561172768,1.31451243455019,1.28688357274827,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,78.660148391275,3.1310763276426736,25.431915329122884,1.40537906900565,4.18706647811088,65.5501236634,percent_activity,1.47712125471966,25.1223988686653,"[""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active""]",1.36430419339355,1.31523363864953,1.28609875532341,20,cell cycle